[go: up one dir, main page]

MX2022014094A - Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer. - Google Patents

Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.

Info

Publication number
MX2022014094A
MX2022014094A MX2022014094A MX2022014094A MX2022014094A MX 2022014094 A MX2022014094 A MX 2022014094A MX 2022014094 A MX2022014094 A MX 2022014094A MX 2022014094 A MX2022014094 A MX 2022014094A MX 2022014094 A MX2022014094 A MX 2022014094A
Authority
MX
Mexico
Prior art keywords
treatment
preparations
cancer
formulation
pharmaceutical formulations
Prior art date
Application number
MX2022014094A
Other languages
English (en)
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2022014094A publication Critical patent/MX2022014094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica de derivados de 5-fluoropirimidina o una sal, solvato o hidrato de los mismos para su administración oral, en donde la formulación es una composición simple que se ingiere de manera simple, más segura, conveniente, no invasiva, con versatilidad y en donde lo más importante es la conformidad del paciente para su administración oral con una conformidad, seguridad y biodisponibilidad mejoradas. Además, se divulga un proceso para la preparación, composición y métodos de administración, dosificaciones de la formulación y su uso para el tratamiento de cánceres y sus complicaciones asociadas.
MX2022014094A 2020-05-19 2021-05-17 Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer. MX2022014094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041020998 2020-05-19
PCT/IB2021/054199 WO2021234532A1 (en) 2020-05-19 2021-05-17 Pharmaceutical formulations and their preparations for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022014094A true MX2022014094A (es) 2022-12-08

Family

ID=78707794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014094A MX2022014094A (es) 2020-05-19 2021-05-17 Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.

Country Status (11)

Country Link
US (1) US20250186435A1 (es)
EP (1) EP4153137A4 (es)
JP (1) JP2023528266A (es)
KR (1) KR20230012572A (es)
AU (1) AU2021275620A1 (es)
BR (1) BR112022022796A2 (es)
CA (1) CA3178648A1 (es)
IL (1) IL298204A (es)
MX (1) MX2022014094A (es)
WO (1) WO2021234532A1 (es)
ZA (1) ZA202212702B (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
ATE540679T1 (de) * 2004-04-29 2012-01-15 Taiho Pharmaceutical Co Ltd Verfahren zur verringerung der gastrointestinalen toxizität durch verabreichung von tegafur
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN103156877B (zh) * 2011-12-13 2015-11-25 深圳海王药业有限公司 一种卡培他滨速释微丸及其制备方法
CA2958332A1 (en) * 2014-09-26 2016-03-31 Intas Pharmaceuticals Ltd. Pharmaceutical composition having improved content uniformity
CN104739800A (zh) * 2015-02-03 2015-07-01 吉林修正药业新药开发有限公司 一种卡培他滨片组合物及其制备方法
US20200054659A1 (en) * 2015-06-13 2020-02-20 Intas Pharmaceuticals Ltd. Extended release capecitabine capsules
CN109414438A (zh) * 2016-06-28 2019-03-01 塞尔利克斯生物私人有限公司 用于治疗癌症的组合物和方法
IN201817045551A (es) * 2018-12-03 2018-12-28

Also Published As

Publication number Publication date
AU2021275620A1 (en) 2022-12-08
WO2021234532A1 (en) 2021-11-25
EP4153137A1 (en) 2023-03-29
IL298204A (en) 2023-01-01
JP2023528266A (ja) 2023-07-04
BR112022022796A2 (pt) 2022-12-13
US20250186435A1 (en) 2025-06-12
EP4153137A4 (en) 2024-07-10
KR20230012572A (ko) 2023-01-26
ZA202212702B (en) 2023-04-26
CA3178648A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
JOP20210171A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
CY1125292T1 (el) Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
BR112021023901A2 (pt) Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer
ES2902136T3 (es) Composiciones farmacéuticas que comprenden un fármaco antirretrovírico y un potenciador farmacocinético
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2024001777A (es) Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
NZ784949A (en) Ripretinib for treating gastrointestinal stromal tumors
BR112023006337A2 (pt) Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
ES2804324T3 (es) Composiciones que contienen extractos de Curcuma longa y Equinácea angustifolia que son útiles para reducir la inflamación y el dolor periféricos
BR112019001423A2 (pt) formulação farmacêutica contendo esomeprazol ou sal farmaceuticamente aceitável e método de preparação
CL2020000271A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.
JP2016516773A5 (es)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
AR122024A1 (es) Formulaciones de liposomas para el tratamiento de cánceres y de la resistencia a los medicamentos de los cánceres
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
MX390101B (es) Tratamiento medico que comprende administracion enteral de edaravona
MX2022014094A (es) Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.
BR112014004339A2 (pt) suspensão oral
MX2023005295A (es) Tratamiento contra el cancer resistente a platino.
MX2025010161A (es) Conjugados de anticuerpo-farmaco que comprenden derivados de trabectedina y lurbinectedina